We Can Medicines Co., Ltd. (6929.TWO)
TWD 37.5
(0.0%)
TWD 37.5
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 3.12 Billion | 3.3 Billion | 2.79 Billion | 2.66 Billion |
| Cost of Revenue | 2.09 Billion | 2.19 Billion | 1.87 Billion | 1.79 Billion |
| Gross Profit | 1.02 Billion | 1.11 Billion | 916.54 Million | 868.44 Million |
| Operating Expenses | 1 Billion | 990.45 Million | 886.12 Million | 833.86 Million |
| Selling, General and Administrative Expenses | 1 Billion | 990.45 Million | 886.12 Million | 833.86 Million |
| Research and Development Expenses | - | - | - | - |
| Other Expenses | 21.54 Million | 22.77 Million | 22.84 Million | 21.26 Million |
| Cost and Expenses | 3.1 Billion | 3.18 Billion | 2.76 Billion | 2.63 Billion |
| Operating Income | 42.66 Million | 144.15 Million | 53.32 Million | 55.91 Million |
| Interest Expense | 23.46 Million | 19.08 Million | 14.43 Million | 13.25 Million |
| Income Tax Expense | 6.79 Million | 21.07 Million | - | - |
| Earnings before Tax | 21.6 Million | 121.12 Million | 38.79 Million | 42.7 Million |
| Net Income | 14.8 Million | 100.05 Million | 38.79 Million | 42.7 Million |
| Earnings Per Share Basic | 0.37 | 2.50 | 0.97 | 1.33 |
| Earnings Per Share Diluted | 0.35 | 2.40 | 0.97 | 1.33 |
| Weighted Average Shares Outstanding | 40 Million | 40 Million | 39.99 Million | 32.11 Million |
| Weighted Average Shares Outstanding (Diluted) | 42.24 Million | 41.72 Million | 39.99 Million | 32.11 Million |
| Gross Margin | 0.33 | 0.34 | 0.33 | 0.33 |
| EBIT Margin | 0.10 | 0.12 | 0.10 | 0.10 |
| Profit Margin | 0.00 | 0.03 | 0.01 | 0.02 |
| EBITDA | 321.24 Million | 393.76 Million | 266.98 Million | 253.52 Million |
| Earnings Before Tax Margin | 0.01 | 0.04 | 0.02 | 0.02 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 823.87 Million | 818.09 Million | 812.2 Million | 3.12 Billion | 774.27 Million | 764.83 Million |
| Cost of Revenue | 545.61 Million | 522.67 Million | 543.2 Million | 2.09 Billion | 538.43 Million | 513.44 Million |
| Gross Profit | 278.26 Million | 295.41 Million | 268.99 Million | 1.02 Billion | 235.84 Million | 251.39 Million |
| Operating Expenses | 285.42 Million | 283.58 Million | 260.52 Million | 1 Billion | 244.25 Million | 252.86 Million |
| Selling, General and Administrative Expenses | 285.42 Million | 283.58 Million | 260.52 Million | - | 244.25 Million | 252.86 Million |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 7.35 Million | 9.74 Million | 3.22 Million | 20.49 Million | 8.35 Million | 2.44 Million |
| Cost and Expenses | 831.04 Million | 806.25 Million | 803.72 Million | 3.1 Billion | 782.69 Million | 766.3 Million |
| Operating Income | 663 Thousand | 21.67 Million | 11.97 Million | 42.66 Million | -2000.00 | 1.22 Million |
| Interest Expense | 6.7 Million | 7.69 Million | 6.66 Million | 23.46 Million | 5.67 Million | 5.79 Million |
| Income Tax Expense | -2.77 Million | 3.17 Million | 1.82 Million | 6.79 Million | -1.65 Million | 1.8 Million |
| Earnings before Tax | -6.07 Million | 13.97 Million | 7.71 Million | 21.6 Million | -5.67 Million | -4.57 Million |
| Net Income | -3.29 Million | 10.8 Million | 5.88 Million | 14.8 Million | -4.02 Million | -6.37 Million |
| Earnings Per Share Basic | -0.08 | 0.27 | 0.15 | - | -0.10 | -0.16 |
| Earnings Per Share Diluted | -0.08 | 0.26 | 0.14 | - | -0.10 | -0.16 |
| Weighted Average Shares Outstanding | 41.18 Million | 40.02 Million | 40.01 Million | 40 Million | 40.24 Million | 40.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 41.18 Million | 41.56 Million | 41.9 Million | 42.24 Million | 40.24 Million | 41.11 Million |
| Gross Margin | 0.34 | 0.36 | 0.33 | 0.33 | 0.30 | 0.33 |
| EBIT Margin | 0.09 | 0.12 | 0.10 | - | 0.09 | 0.09 |
| Profit Margin | -0.00 | 0.01 | 0.01 | 0.00 | -0.01 | -0.01 |
| EBITDA | 76.45 Million | 95.76 Million | 82.9 Million | - | 70.82 Million | 69.11 Million |
| Earnings Before Tax Margin | 0.00 | 0.03 | 0.01 | 0.01 | -0.00 | 0.00 |
CZFS
SEBC
VIRINCHI
ASAZF
UNCFF
8513